Last reviewed · How we verify

Morphine Patient Controlled Analgesia

Istituti Ospitalieri di Cremona · FDA-approved active Small molecule

Morphine binds to opioid receptors in the central nervous system to block pain signal transmission and provide analgesia.

Morphine binds to opioid receptors in the central nervous system to block pain signal transmission and provide analgesia. Used for Acute postoperative pain, Acute moderate to severe pain in hospitalized patients.

At a glance

Generic nameMorphine Patient Controlled Analgesia
Also known asMORPHİNE PCA
SponsorIstituti Ospitalieri di Cremona
Drug classOpioid analgesic
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Morphine is a mu-opioid receptor agonist that acts on the central nervous system to reduce the perception of pain and emotional response to pain. Patient-controlled analgesia (PCA) is a delivery method that allows patients to self-administer doses of morphine within programmed safety limits, improving pain control and patient satisfaction. This formulation is used in acute postoperative and acute pain management settings.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: